A ten-year retrospective study of sepsis in severely burned patients treated with or without silver sulfadiazinate.
Three groups of extensive burn patients of the surgical intensive care unit (ICU) have been compared: Group I: twenty patients, who were treated locally without silver sulfadiazinate (1968-1970); Group II: the twenty first patients topically treated with silver sulfadiazinate (1970-1972); Group III: twenty similarly treated patients, with silver sulfadiazinate, six years later (1976-1977). The groups are statistically comparable. All bacteriological samples were computerized; the chi-square method was used for statistical analysis of the data. The main conclusions are: (A) Silver sulfadiazinate treatment reduced Pseudomonas aeruginosa and Proteus sepsis. No change in Coliform bacilli sepsis was observed. After six years, a rise in Klebsiella sepsis and Candida sepsis was noted. (B) A quantitative estimate of infections in each group was made by measuring the percentage of positive samples, taking into account the five above-mentioned strains. In the beginning, silver sulfadiazinate reduced quantitative sepsis, but this benefit decreased after six years; the same evolution was demonstrated for positive blood bacteriology; severe septicaemia showed a parallel pattern.
D002056:Burns / Q000150:complications / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D012189:Retrospective Studies; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control*; D012837:Silver Sulfadiazine / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000627:therapeutic use*
D013411:Sulfadiazine; D012837:Silver Sulfadiazine